Top-down production of drug nanocrystals: nanosuspension stabilization, miniaturization and transformation into solid products.

[1]  Ludo Froyen,et al.  Alternative matrix formers for nanosuspension solidification: Dissolution performance and X-ray microanalysis as an evaluation tool for powder dispersion. , 2008, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[2]  L. Froyen,et al.  Microcrystalline cellulose, a useful alternative for sucrose as a matrix former during freeze-drying of drug nanosuspensions - a case study with itraconazole. , 2008, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[3]  L. Froyen,et al.  Drying of crystalline drug nanosuspensions-the importance of surface hydrophobicity on dissolution behavior upon redispersion. , 2008, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[4]  Joseph Wong,et al.  Suspensions for intravenous (IV) injection: a review of development, preclinical and clinical aspects. , 2008, Advanced drug delivery reviews.

[5]  Wenting Dai,et al.  Studies on pharmacokinetics and tissue distribution of oridonin nanosuspensions. , 2008, International journal of pharmaceutics.

[6]  J-Y Choi,et al.  Characteristics of polymers enabling nano-comminution of water-insoluble drugs. , 2008, International journal of pharmaceutics.

[7]  Z. Deng,et al.  Understanding a relaxation behavior in a nanoparticle suspension for drug delivery applications. , 2008, International journal of pharmaceutics.

[8]  Gary Eichenbaum,et al.  Method for screening of solid dispersion formulations of low-solubility compounds--miniaturization and automation of solvent casting and dissolution testing. , 2008, International journal of pharmaceutics.

[9]  Pardeep Gupta,et al.  Effect of arginine hydrochloride and hydroxypropyl cellulose as stabilizers on the physical stability of high drug loading nanosuspensions of a poorly soluble compound. , 2008, International journal of pharmaceutics.

[10]  Jun Li,et al.  Preparation and characterization of intravenously injectable nimodipine nanosuspension. , 2008, International journal of pharmaceutics.

[11]  Y. M. Rao,et al.  Formulation of Nanosuspensions of Albendazole for Oral Administration , 2008 .

[12]  K. Sigfridsson,et al.  A formulation comparison, using a solution and different nanosuspensions of a poorly soluble compound. , 2007, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[13]  S. Roberds,et al.  1,3-Dicyclohexyl urea nanosuspension for intravenous steady-state delivery in rats , 2007 .

[14]  M. Ghorab,et al.  Nanosuspension as an ophthalmic delivery system for certain glucocorticoid drugs. , 2007, International journal of pharmaceutics.

[15]  Filippos Kesisoglou,et al.  Nanosizing--oral formulation development and biopharmaceutical evaluation. , 2007, Advanced drug delivery reviews.

[16]  Joseph Wong,et al.  Itraconazole IV nanosuspension enhances efficacy through altered pharmacokinetics in the rat. , 2007, International journal of pharmaceutics.

[17]  G Vergnault,et al.  Pharmacokinetic evaluation of oral fenofibrate nanosuspensions and SLN in comparison to conventional suspensions of micronized drug. , 2007, Advanced drug delivery reviews.

[18]  P Augustijns,et al.  Characterization of physico-chemical properties and pharmaceutical performance of sucrose co-freeze-dried solid nanoparticulate powders of the anti-HIV agent loviride prepared by media milling. , 2007, International journal of pharmaceutics.

[19]  Po-Chang Chiang,et al.  Pharmacokinetic evaluation of a 1,3-dicyclohexylurea nanosuspension formulation to support early efficacy assessment , 2007, Nanoscale Research Letters.

[20]  Gary Eichenbaum,et al.  Screening method to identify preclinical liquid and semi-solid formulations for low solubility compounds: miniaturization and automation of solvent casting and dissolution testing. , 2007, Journal of pharmaceutical sciences.

[21]  Jing Chen,et al.  Parallel screening approach to identify solubility-enhancing formulations for improved bioavailability of a poorly water-soluble compound using milligram quantities of material. , 2007, International journal of pharmaceutics.

[22]  Filippos Kesisoglou,et al.  Application of Nanoparticles in Oral Delivery of Immediate Release Formulations , 2007 .

[23]  Y. M. Rao,et al.  Improved Bioavailability of Albendazole Following Oral Administration of Nanosuspension in Rats , 2007 .

[24]  K. Johnston,et al.  Turbidimetric measurement and prediction of dissolution rates of poorly soluble drug nanocrystals. , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[25]  T. Tan,et al.  Preparation of Azithromycin Nanosuspensions by High Pressure Homogenization and its Physicochemical Characteristics Studies , 2007, Drug development and industrial pharmacy.

[26]  Dianrui Zhang,et al.  Preparation and Characterization of an Oridonin Nanosuspension for Solubility and Dissolution Velocity Enhancement , 2007, Drug development and industrial pharmacy.

[27]  K. Amighi,et al.  Preparation and in vitro/in vivo evaluation of nano-sized crystals for dissolution rate enhancement of ucb-35440-3, a highly dosed poorly water-soluble weak base. , 2006, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[28]  J. Donnelly,et al.  Pharmacokinetics of Itraconazole and Hydroxyitraconazole in Healthy Subjects after Single and Multiple Doses of a Novel Formulation , 2006, Antimicrobial Agents and Chemotherapy.

[29]  G. Van den Mooter,et al.  Evaluation of Inutec SP1 as a new carrier in the formulation of solid dispersions for poorly soluble drugs. , 2006, International journal of pharmaceutics.

[30]  Rainer H Müller,et al.  Spray coated pellets as carrier system for mucoadhesive drug nanocrystals. , 2006, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[31]  Y. Cheng,et al.  Critical freezing rate in freeze drying nanocrystal dispersions. , 2006, Journal of controlled release : official journal of the Controlled Release Society.

[32]  M. Odomi,et al.  Effect of particle size reduction on dissolution and oral absorption of a poorly water-soluble drug, cilostazol, in beagle dogs. , 2006, Journal of controlled release : official journal of the Controlled Release Society.

[33]  Faris Nadiem Bushrab,et al.  Manufacturing of Nanoparticles by Milling and Homogenization Techniques , 2006 .

[34]  Ram B. Gupta,et al.  Fundamentals of Drug Nanoparticles , 2006 .

[35]  B. Rabinow,et al.  Injectable Nanoparticles for Efficient Drug Delivery , 2006 .

[36]  Rainer H Müller,et al.  Characterization of nebulized buparvaquone nanosuspensions—effect of nebulization technology , 2005, Journal of drug targeting.

[37]  K. Amighi,et al.  Preparation and characterization of nanocrystals for solubility and dissolution rate enhancement of nifedipine. , 2005, International journal of pharmaceutics.

[38]  Jonghwi Lee,et al.  Role of polymeric stabilizers for drug nanocrystal dispersions , 2005 .

[39]  C. Ahn,et al.  Amphiphilic amino acid copolymers as stabilizers for the preparation of nanocrystal dispersion. , 2005, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[40]  Christian Joachim,et al.  To be nano or not to be nano? , 2005, Nature materials.

[41]  G Vergnault,et al.  Nanosuspension Formulations for Low-Soluble Drugs: Pharmacokinetic Evaluation Using Spironolactone as Model Compound , 2005, Drug development and industrial pharmacy.

[42]  Gloria Kwei,et al.  The role of biopharmaceutics in the development of a clinical nanoparticle formulation of MK-0869: a Beagle dog model predicts improved bioavailability and diminished food effect on absorption in human. , 2004, International journal of pharmaceutics.

[43]  Vandana B. Patravale,et al.  Current strategies for engineering drug nanoparticles , 2004 .

[44]  Christopher T. Walsh,et al.  Drugs as materials: valuing physical form in drug discovery , 2004, Nature Reviews Drug Discovery.

[45]  Georg Achleitner,et al.  Development of an intravenously injectable chemically stable aqueous omeprazole formulation using nanosuspension technology. , 2004, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[46]  J E Kipp,et al.  The role of solid nanoparticle technology in the parenteral delivery of poorly water-soluble drugs. , 2004, International journal of pharmaceutics.

[47]  Cornelia M Keck,et al.  Challenges and solutions for the delivery of biotech drugs--a review of drug nanocrystal technology and lipid nanoparticles. , 2004, Journal of biotechnology.

[48]  Barrett E. Rabinow,et al.  Nanosuspensions in drug delivery , 2004, Nature Reviews Drug Discovery.

[49]  E. Merisko-Liversidge,et al.  Insulin Nanoparticles: A Novel Formulation Approach for Poorly Water Soluble Zn-Insulin , 2004, Pharmaceutical Research.

[50]  Raviraj M. Kulkarni,et al.  Nanosuspensions: a promising drug delivery strategy , 2004, The Journal of pharmacy and pharmacology.

[51]  Matt Peterson,et al.  Application of high throughput technologies to drug substance and drug product development , 2004, Comput. Chem. Eng..

[52]  K. Johnston,et al.  Nanoparticle Engineering Processes for Enhancing the Dissolution Rates of Poorly Water Soluble Drugs , 2004, Drug development and industrial pharmacy.

[53]  Jonghwi Lee.  Drug nano- and microparticles processed into solid dosage forms: physical properties. , 2003, Journal of pharmaceutical sciences.

[54]  Chris McNulty,et al.  A High-Throughput Combinatorial Approach for the Discovery of a Cremophor EL-Free Paclitaxel Formulation , 2003, Pharmaceutical Research.

[55]  C Olbrich,et al.  Formulation of amphotericin B as nanosuspension for oral administration. , 2003, International journal of pharmaceutics.

[56]  Elaine Merisko-Liversidge,et al.  Nanosizing: a formulation approach for poorly-water-soluble compounds. , 2003, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[57]  O. Kayser,et al.  DissoCubes‚ÄîA Novel Formulation for Poorly Soluble and Poorly Bioavailable Drugs , 2002 .

[58]  J. Hadgraft,et al.  Modified-Release Drug Delivery Technology , 2002 .

[59]  D. Newbury.  X-Ray Microanalysis in the Variable Pressure (Environmental) Scanning Electron Microscope , 2002, Journal of research of the National Institute of Standards and Technology.

[60]  Cesario Z. Cerna,et al.  Effect of Nanonization on Absorption of 301029: Ex Vivo and In Vivo Pharmacokinetic Correlations Determined by Liquid Chromatography/Mass Spectrometry , 2002, Pharmaceutical Research.

[61]  J. Remon,et al.  In vivo evaluation of matrix pellets containing nanocrystalline ketoprofen. , 2002, International journal of pharmaceutics.

[62]  R. Müller,et al.  Buparvaquone mucoadhesive nanosuspension: preparation, optimisation and long-term stability. , 2002, International journal of pharmaceutics.

[63]  R. Müller,et al.  Production and Characterization of a Budesonide Nanosuspension for Pulmonary Administration , 2002, Pharmaceutical Research.

[64]  J. Rieger,et al.  Organic Nanoparticles in the Aqueous Phase-Theory, Experiment, and Use. , 2001, Angewandte Chemie.

[65]  C. Stevens,et al.  Polymeric surfactants based on inulin, a polysaccharide extracted from chicory. 1. Synthesis and interfacial properties. , 2001, Biomacromolecules.

[66]  Helmut Hahn,et al.  Atovaquone Nanosuspensions Show Excellent Therapeutic Effect in a New Murine Model of Reactivated Toxoplasmosis , 2001, Antimicrobial Agents and Chemotherapy.

[67]  J. Remon,et al.  An oral controlled release matrix pellet formulation containing nanocrystalline ketoprofen. , 2001, International journal of pharmaceutics.

[68]  R. Müller,et al.  Nanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the future. , 2001, Advanced drug delivery reviews.

[69]  R. Müller,et al.  Production and characterisation of highly concentrated nanosuspensions by high pressure homogenisation. , 2001, International journal of pharmaceutics.

[70]  R. Müller,et al.  Production and characterisation of mucoadhesive nanosuspensions for the formulation of bupravaquone. , 2001, International journal of pharmaceutics.

[71]  A. Bauer-Brandl,et al.  Properties of Fujicalin®, a New Modified Anhydrous Dibasic Calcium Phosphate for Direct Compression: Comparison with Dicalcium Phosphate Dihydrate , 2001, Drug development and industrial pharmacy.

[72]  Donald L. Wise,et al.  Nanosuspensions: A Formulation Approach for Poorly Soluble and Poorly Bioavailable Drugs , 2000 .

[73]  R. Müller,et al.  Nanosuspensions of poorly soluble drugs--reproducibility of small scale production. , 2000, International journal of pharmaceutics.

[74]  R. Müller,et al.  Nanosuspensions as a new approach for the formulation for the poorly soluble drug tarazepide. , 2000, International journal of pharmaceutics.

[75]  H. Bosch,et al.  An in-vitro assessment of a NanoCrystal beclomethasone dipropionate colloidal dispersion via ultrasonic nebulization. , 1999, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[76]  R. Müller,et al.  An investigation into the distribution of lecithins in nanosuspension systems using low frequency dielectric spectroscopy. , 1999, International journal of pharmaceutics.

[77]  G. Na,et al.  Physical Stability of Ethyl Diatrizoate Nanocrystalline Suspension in Steam Sterilization , 1999, Pharmaceutical Research.

[78]  A. Fasano,et al.  Innovative strategies for the oral delivery of drugs and peptides. , 1998, Trends in biotechnology.

[79]  Rainer H. Müller,et al.  Nanosuspensions for the formulation of poorly soluble drugs: I. Preparation by a size-reduction technique , 1998 .

[80]  J. M. Shaw,et al.  Formulation and Antitumor Activity Evaluation of Nanocrystalline Suspensions of Poorly Soluble Anticancer Drugs , 1996, Pharmaceutical Research.

[81]  G. Liversidge,et al.  Drug particle size reduction for decreasing gastric irritancy and enhancing absorption of naproxen in rats , 1995 .

[82]  G. Liversidge,et al.  Particle size reduction for improvement of oral bioavailability of hydrophobic drugs: I. Absolute oral bioavailability of nanocrystalline danazol in beagle dogs , 1995 .

[83]  Á. Delgado,et al.  Stability of Monodisperse Zinc Sulfide Colloidal Dispersions , 1995 .

[84]  C. V. Oss,et al.  Interfacial Forces in Aqueous Media , 1994 .

[85]  B. Derjaguin,et al.  Theory of the stability of strongly charged lyophobic sols and of the adhesion of strongly charged particles in solutions of electrolytes , 1993 .

[86]  Y. Ogawa,et al.  Improved oral absorption of a poorly water-soluble drug, HO-221, by wet-bead milling producing particles in submicron region. , 1993, Chemical & pharmaceutical bulletin.

[87]  C. J. Oss,et al.  DLVO and Non-DLVO Interactions in Hectorite , 1990 .

[88]  E. Verwey,et al.  Theory of the stability of lyophobic colloids. , 1955, The Journal of physical and colloid chemistry.

[89]  L. Froyen,et al.  Scaling down of drug nanosuspension production: Process aspects and physico-chemical characterization , 2008 .

[90]  K. Amighi,et al.  Nifedipine nanocrystals : pharmacokinetic evaluation in the rat and permeability studies in Caco-2/HT29-5M21 (co)-cultures , 2006 .

[91]  Rainer H Müller,et al.  Drug nanocrystals of poorly soluble drugs produced by high pressure homogenisation. , 2006, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[92]  R. W. Wood,et al.  Nebulization of NanoCrystals™: Production of a Respirable Solid-in-Liquid-in-Air Colloidal Dispersion , 2004, Pharmaceutical Research.

[93]  M. Rao,et al.  Nanosuspensions as the most promising approach in nanoparticulate drug delivery systems. , 2004, Die Pharmazie.

[94]  C. Lipinski.  Poor aqueous solubility-an industry wide problem in drug discovery , 2002 .

[95]  S. Jahnke.  The theory of high-pressure homogenization , 2001 .

[96]  K Borner,et al.  Preparation of a clofazimine nanosuspension for intravenous use and evaluation of its therapeutic efficacy in murine Mycobacterium avium infection. , 2000, The Journal of antimicrobial chemotherapy.

[97]  R. H. Müller,et al.  Nanosuspensionen: Formulierungen für schwerlösliche Arzneistoffe mit geringer Bioverfügbarkeit. 2. Mitteilung: Stabilität, biopharmazeutische Aspekte, mögliche Arzneiformen und Zulassungsfragen , 1999 .

[98]  R. H. Müller,et al.  Nanosuspensionen - Formulierungen für schwerlösliche Arzneistoffe mit geringer Bioverfügbarkeit. 1. Mitteilung: Herstellung und Eigenschaften , 1999 .

[99]  H. Bosch,et al.  Sterile Filtration of NanoCrystal™ Drug Formulations , 1997 .

[100]  Raymond C Rowe,et al.  Handbook of Pharmaceutical Excipients , 1994 .

[101]  J. Israelachvili.  Intermolecular and surface forces , 1985 .

[102]  J. Swarbrick.  Drugs and the pharmaceutical sciences , 1975 .

[103]  J. A. V. BUTLER,et al.  Theory of the Stability of Lyophobic Colloids , 1948, Nature.